RxDoctor Payments Data

Cassandra Smith

Family · Triadelphia, WVNPI 1568641835

Payments from drug & device makers

$1,202in general payments, 2019–2025

Across 50 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$310
  • AstraZeneca$191
  • Esperion Therapeutics, Inc.$186
  • Actelion Pharmaceuticals US, Inc.$120
  • Johnson & Johnson$68
  • Novo Nordisk$56
  • plus $272 from 10 others

What the payments were for

  • Food & beverage$1,07289%
  • Education$13011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,202 in reported general payments places this provider in the 70th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$40,328
Medicare patients
418
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban382$354,551
EntrestoSacubitril/Valsartan117$112,504
Repatha SureclickEvolocumab114$82,863
JardianceEmpagliflozin88$58,565
XareltoRivaroxaban46$39,996
FarxigaDapagliflozin Propanediol37$35,439
Praluent PenAlirocumab30$16,872
BrilintaTicagrelor15$10,605
VascepaIcosapent Ethyl15$8,014
Metoprolol Succinate556$7,739
Rosuvastatin Calcium260$4,031
Atorvastatin Calcium317$3,276
Ezetimibe161$3,111
Ranolazine ErRanolazine24$2,773
Valsartan68$2,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$354,551382 claims
Boehringer IngelheimJardiance$15$58,56588 claims
AstraZenecaFarxiga, Brilinta$191$46,04452 claims
Johnson & JohnsonXarelto$68$39,99646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,507 family providers in West Virginia.

Other family in Triadelphia

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →